Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis.

Document Type

Article

Publication Date

11-2019

Identifier

DOI: 10.1002/ppul.24511

Abstract

Management of infections in patients with cystic fibrosis (CF) presents challenges for healthcare providers, including the eradication of initial acquisition, treatment of acute exacerbations, and chronic infection with suppressive therapy. Inhaled antimicrobial therapy for infections in patients with CF has been used in these capacities, often in an effort to achieve optimal concentrations in sputum for antimicrobial efficacy while mitigating potential toxicities associated with systemic therapy. Unfortunately, there are few commercially available products formulated for inhalation, resulting in the off-label use of other formulations, such as intravenous products, administered via nebulization. This review aims to examine the evidence supporting the efficacy of these off-label formulations for management of acute and chronic infections associated with CF, as well as adverse effects associated with their use.

Journal Title

Pediatric pulmonology

Volume

54 Suppl 3

Issue

Suppl 3

First Page

27

Last Page

45

MeSH Keywords

Administration, Inhalation; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Off-Label Use; Pneumonia, Bacterial; Pseudomonas Infections; Pseudomonas aeruginosa

Keywords

antimicrobials; cystic fibrosis

Link to Full Text
Library Record

Share

COinS